April 17: The FDA granted accelerated approval to an additional indication for Tecentriq (atezolizumab) to treat people with locally advanced or metastatic urothelial carcinoma who are not eligible for treatment with cisplatin. The agency has approved three indications for the Genentech USA, Inc. infusible in less than a year from its initial May 18, 2016, […]
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.